Skip to main content
Farmacosmo logo

Farmacosmo — Investor Relations & Filings

Ticker · ZJ1 ISIN · IT0005487670 LEI · 815600ABEDB6F0BDDE28 XMIL Wholesale and retail trade
Open in API
Filings indexed 188 across all filing types
Latest filing 2023-02-09 Director's Dealing
Country IT Italy
Listing XMIL ZJ1

About Farmacosmo

https://www.farmacosmo.com/

Farmacosmo is an e-commerce company that operates an online platform for health, beauty, and personal care products. The company's core business is the online sale of a broad range of items, including parapharmaceuticals, supplements, cosmetics, personal care products, baby supplies, and pet care essentials. Managing its platform in-house, Farmacosmo offers a catalog of over 80,000 products from various brands. The company aims to provide a comprehensive wellness destination by combining the offerings of a pharmacy and a cosmetics retailer, supported by expert advice from professionals.

Recent filings

Filing Released Lang Actions
Farmacosmo - Fabio de Concilio - Internal Dealing
Director's Dealing Classification · 100% confidence The document is a regulatory filing notification from Euronext Growth Milan, dated February 9, 2023. The 'Oggetto' (Subject) is 'Dealing'. The template used is titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' This explicitly concerns transactions (dealing) by directors or senior management (e.g., 'Presidente del CdA e Amministratore Delegato' - Chairman of the Board and CEO). This perfectly matches the definition for Director's Dealing (DIRS).
2023-02-09 Italian
Farmacosmo - Gargiulo&Maiello - Internal Dealing
Director's Dealing Classification · 99% confidence The document is an official notification from Euronext Growth Milan, dated February 7, 2023. The subject ('Oggetto') is 'Dealing'. The template used is titled 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' Furthermore, Section 2, 'Motivo della notifica' (Reason for the notification), specifically mentions 'Altro da persone che esercitano funzioni di amministrazione, di controllo o di direzione, o da persona strettamente associata' (Other from persons discharging managerial responsibilities or persons closely associated) and details transactions involving individuals associated with the company (Alessandro Maiello and Gargiulo&Maiello S.p.A.). This structure perfectly matches the definition of Director's Dealing (insider trades by executives/directors).
2023-02-07 English
Farmacosmo - Fabio de Concilio - Internal Dealing
Director's Dealing Classification · 100% confidence The document is a 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' The 'Oggetto' (Subject) field explicitly states 'Dealing' and mentions a specific internal person ('Farmacosmo - Fabio de Concilio - Internal'). This structure and content directly correspond to the reporting requirements for insider trading or director/executive share transactions. This matches the definition for Director's Dealing (DIRS). The document is a formal notification, not a general regulatory filing (RNS) or a report announcement (RPA), as it contains the specific transaction details (even if the full details are in an attachment, the template itself is the core disclosure).
2023-02-03 Italian
Closing Per L’acquisizione Del Portale Bau Cosmesi Ad Esito Dell’operazione Farmacosmo Deterrà Il 67% Della Societa’ Proprietaria Del Portale
Environmental & Social Information Classification · 99% confidence The document is identified by the header 'Informazione Regolamentata n. 20253-15-2023' and the object 'Oggetto' which describes a 'Closing Per L'acquisizione Del Portale Bau'. The content details the completion of an acquisition (M&A activity) resulting in Farmacosmo holding a 67% stake in the new entity, including details about the transaction, new board appointments, and financial metrics of the acquired asset. This clearly falls under the category of Merger & Acquisition (M&A) activity or a significant corporate transaction. The most fitting code is TAR (M&A Activity). Although it is a press release, the core subject matter is the transaction itself, not just the announcement of a report (RPA) or a general regulatory filing (RNS).
2023-02-02 Italian
Farmacosmo Risultati Del Primo Periodo Di Esercizio Dei Warrant Farmacosmo 2022-2025
Share Issue/Capital Change Classification · 99% confidence The document is a formal communication from Farmacosmo S.p.A. to Euronext Growth Milan, identified by the header "Informazione Regolamentata n. 20253-14-2023". The subject ("Oggetto") is "Farmacosmo Risultati Del Primo Periodo Di Esercizio Dei Warrant Farmacosmo 2022-2025". The content explicitly states the results (zero exercises) for the first exercise period of the warrants and directs the reader to an attachment ("Vedi allegato"). Although it contains some business context, its primary function is to announce a specific corporate action result related to capital instruments (warrants) and direct the reader to the full details (the attachment). Since the document itself is short and primarily serves as a notification that a specific event result is available, it fits the description of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that the topic is a specific corporate action result (warrant exercise), and it is presented as a press release/regulated information notice pointing to an attachment, RPA is a strong candidate, but RNS is the most appropriate general regulatory fallback for specific, non-standard reports like this, especially when the core information is brief and points elsewhere. However, since the document details the outcome of a specific corporate event (warrant exercise period closure) which is a mandatory disclosure, and it is not a standard financial report (10-K, IR, ER), it falls under specific regulatory announcements. Given the options, and the nature of reporting on warrant exercise results, this is a specific regulatory disclosure. If we interpret 'Report Publication Announcement' (RPA) as the announcement *of* the report, and this document *is* the announcement of the result, RPA is plausible. However, since it is a direct disclosure of a corporate event result rather than just announcing the publication of a larger document, and it is highly specific, RNS (Regulatory Filings - general fallback) is often used for such specific, non-periodic disclosures in Italian markets when a more specific code isn't available. Let's re-evaluate based on the definitions. It is not an ER, IR, or 10-K. It is not about management change (MANG) or director dealing (DIRS). It is about capital instruments, but not a financing update (CAP) or share issue (SHA/POS). It is a specific disclosure of an event outcome. RNS is the best fit as a specific regulatory disclosure that doesn't match the other defined categories perfectly, although it is very close to a CAP or SHA event update.
2023-01-31 Italian
Farmacosmo - Fabio de Concilio - Internal Dealing
Director's Dealing Classification · 99% confidence The document is an official notification filed on January 31, 2023, with the subject line 'Dealing' and explicitly references a 'Template for notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.' The content details a transaction by 'Fabio de Concilio' who holds the position of 'Presidente del CdA e Amministratore Delegato' (Chairman of the Board and CEO) of FARMACOSMO. This type of filing, reporting insider transactions by directors/executives, directly corresponds to the definition of Director's Dealing.
2023-01-31 Portuguese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.